Cargando…

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients. We performed this retrospective cohort study and identified incident TB cases in the Taiwan National Tuberculo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Meng-Rui, Lee, Ming-Chia, Chang, Chia-Hao, Liu, Chia-Jung, Chang, Lih-Yu, Zhang, Jun-Fu, Wang, Jann-Yuan, Lee, Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678265/
https://www.ncbi.nlm.nih.gov/pubmed/31252593
http://dx.doi.org/10.3390/jcm8070923
_version_ 1783441059608526848
author Lee, Meng-Rui
Lee, Ming-Chia
Chang, Chia-Hao
Liu, Chia-Jung
Chang, Lih-Yu
Zhang, Jun-Fu
Wang, Jann-Yuan
Lee, Chih-Hsin
author_facet Lee, Meng-Rui
Lee, Ming-Chia
Chang, Chia-Hao
Liu, Chia-Jung
Chang, Lih-Yu
Zhang, Jun-Fu
Wang, Jann-Yuan
Lee, Chih-Hsin
author_sort Lee, Meng-Rui
collection PubMed
description While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients. We performed this retrospective cohort study and identified incident TB cases in the Taiwan National Tuberculosis Registry from 2008 to 2014. These cases were further classified into antiplatelet users and non-users according to the use of antiplatelet agents prior to the TB diagnosis, and the cohorts were matched using propensity scores (PSs). The primary outcome was survival after a TB diagnosis. In total, 74,753 incident TB cases were recruited; 9497 (12.7%) were antiplatelet users, and 7764 (10.4%) were aspirin (ASA) users. A 1:1 PS-matched cohort with 8864 antiplatelet agent users and 8864 non-users was created. After PS matching, antiplatelet use remained associated with a longer survival (adjusted hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.88–0.95, p < 0.0001). The risk of major bleeding was not elevated in antiplatelet users compared to non-users (p = 0.604). This study shows that use of antiplatelet agents has been associated with improved survival in TB patients. The immunomodulatory and anti-inflammatory effects of antiplatelet agents in TB disease warrant further investigation. Antiplatelets are promising as an adjunct anti-TB therapy.
format Online
Article
Text
id pubmed-6678265
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66782652019-08-19 Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study Lee, Meng-Rui Lee, Ming-Chia Chang, Chia-Hao Liu, Chia-Jung Chang, Lih-Yu Zhang, Jun-Fu Wang, Jann-Yuan Lee, Chih-Hsin J Clin Med Article While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients. We performed this retrospective cohort study and identified incident TB cases in the Taiwan National Tuberculosis Registry from 2008 to 2014. These cases were further classified into antiplatelet users and non-users according to the use of antiplatelet agents prior to the TB diagnosis, and the cohorts were matched using propensity scores (PSs). The primary outcome was survival after a TB diagnosis. In total, 74,753 incident TB cases were recruited; 9497 (12.7%) were antiplatelet users, and 7764 (10.4%) were aspirin (ASA) users. A 1:1 PS-matched cohort with 8864 antiplatelet agent users and 8864 non-users was created. After PS matching, antiplatelet use remained associated with a longer survival (adjusted hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.88–0.95, p < 0.0001). The risk of major bleeding was not elevated in antiplatelet users compared to non-users (p = 0.604). This study shows that use of antiplatelet agents has been associated with improved survival in TB patients. The immunomodulatory and anti-inflammatory effects of antiplatelet agents in TB disease warrant further investigation. Antiplatelets are promising as an adjunct anti-TB therapy. MDPI 2019-06-27 /pmc/articles/PMC6678265/ /pubmed/31252593 http://dx.doi.org/10.3390/jcm8070923 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Meng-Rui
Lee, Ming-Chia
Chang, Chia-Hao
Liu, Chia-Jung
Chang, Lih-Yu
Zhang, Jun-Fu
Wang, Jann-Yuan
Lee, Chih-Hsin
Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title_full Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title_fullStr Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title_full_unstemmed Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title_short Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
title_sort use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678265/
https://www.ncbi.nlm.nih.gov/pubmed/31252593
http://dx.doi.org/10.3390/jcm8070923
work_keys_str_mv AT leemengrui useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT leemingchia useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT changchiahao useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT liuchiajung useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT changlihyu useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT zhangjunfu useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT wangjannyuan useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy
AT leechihhsin useofantiplateletagentsandsurvivaloftuberculosispatientsapopulationbasedcohortstudy